Safe aspirin elimination in patients with HeartMate 3 LVAD reduces bleeding risk, offering key clinical practice insights.

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Data analysis was conducted between April and July 2024. Patients who received a de novo HM3 LVAD were randomized 1:1 to aspirin 100 mg/day or placebo with a vitamin K antagonist (VKA) to achieve an ...

Although ctDNA positivity generally meant worse disease-free survival in stage 3 resected colon cancer, patients with ctDNA ...

In the United States, the annual consumption of aspirin is approximately 80 billion tablets, while in the United Kingdom it is approximately 100 tons. Apart from its analgesic and antipyretic ...

The global aspirin drug market is poised for substantial growth over the next decade, with its value expected to increase ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

"I’ve had minor issues, like bad colds that I cured with aspirin, but doctors never come to my home." And it's a simple, ...

Ernest Pharmaceuticals team of scientists has made “exciting,” patient-friendly advances in developing a non-toxic bacterial ...

A team of researchers from the University of Massachusetts Amherst and Ernest Pharmaceuticals is preparing to begin clinical ...

Aspirin triggers BacID (turquoise ... “The genetic engineering steps we took made this strain at least 100 times safer than anything that’s been tried in the past.” In this third-generation ...